A5041611958- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Neuroscience and Neuropharmacology Research
- EEG and Brain-Computer Interfaces
- Genetics and Neurodevelopmental Disorders
- Neurological disorders and treatments
- Pharmaceutical studies and practices
- Neurobiology of Language and Bilingualism
- Cannabis and Cannabinoid Research
- Drug Transport and Resistance Mechanisms
- Neonatal and fetal brain pathology
- Neurological and metabolic disorders
- Glycogen Storage Diseases and Myoclonus
- Metabolism and Genetic Disorders
- Schizophrenia research and treatment
- Antibiotics Pharmacokinetics and Efficacy
- Ion Transport and Channel Regulation
- Autoimmune Neurological Disorders and Treatments
- Attention Deficit Hyperactivity Disorder
- Functional Brain Connectivity Studies
- Musculoskeletal pain and rehabilitation
- Health Systems, Economic Evaluations, Quality of Life
- Diet and metabolism studies
- Ion channel regulation and function
- Tuberous Sclerosis Complex Research
Hospital Universitari i Politècnic La Fe
2016-2025
ERN GUARD-Heart
2024
Mid Atlantic Epilepsy and Sleep Center
2022
Johns Hopkins University
2012-2022
Bethel University
2022
SK Life Science (United States)
2022
University of Freiburg
2022
Evangelisches Krankenhaus Bielefeld
2022
Johns Hopkins Medicine
2022
Diakonie Kork
2022
Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen conventional antiepileptic medication treat drop Lennox–Gastaut syndrome, developmental epileptic encephalopathy.
To evaluate the efficacy and safety of perampanel 2, 4, 8 mg/day added to 1-3 concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial-onset seizures.During this double-blind, placebo-controlled trial, persisting seizures on AEDs were randomized or placebo following a 6-week baseline phase. Perampanel was titrated weekly by 2 maintained at dose achieved for 13 weeks. Primary endpoints median percent change seizure frequency 50% responder rate. Analysis covariance...
Abstract Objective This study investigated early, real‐world outcomes with cenobamate (CNB) in a large series of patients highly drug‐resistant epilepsy within Spanish Expanded Access Program (EAP). Method was multicenter, retrospective, observational 14 hospitals. Inclusion criteria were age ≥18 years, focal seizures, and EAP authorization. Data sourced from patient clinical records. Primary effectiveness endpoints included reductions (100%, ≥90%, ≥75%, ≥50%) or worsening seizure frequency...
Summary Objective To analyze the effectiveness and tolerability of perampanel across different seizure types in routine clinical care patients with idiopathic generalized epilepsy ( IGE ). Methods This multicenter, retrospective, 1‐year observational study collected data from patient records at 21 specialist units Spain. All who were aged ≥12 years, prescribed before December 2016, had a confirmed diagnosis included. Results The population comprised 149 (60 juvenile myoclonic epilepsy, 51...
EXamining everolimus In a Study of Tuberous sclerosis 3 (EXIST-3) demonstrated significantly reduced seizure frequency (SF) with vs placebo. this study, we evaluate the long-term efficacy and safety for tuberous complex (TSC)-associated treatment-refractory seizures.After completion core phase, patients could enter an open-label extension phase receive (target exposure, 3-15 ng/mL) ≥48 weeks. Efficacy end points included change from baseline in average weekly SF expressed as response rate...
To evaluate long-term efficacy (percent seizure frequency reduction and responder rates), safety, tolerability of adjunctive cenobamate (CNB) in an open-label extension (OLE) the randomized, double-blind, placebo-controlled study.Patients (aged 18-70 years) with uncontrolled focal seizures despite treatment 1-3 antiseizure medications who completed 18-week double-blind study (n = 360) could enter OLE, where they underwent a 2-week blinded conversion to CNB (target dose, 300 mg/d; min/max,...
Abstract Objective Dravet syndrome (DS) and Lennox–Gastaut (LGS) are rare treatment‐resistant childhood epilepsies classed as developmental epileptic encephalopathies. ELEKTRA investigated the efficacy safety of soticlestat (TAK‐935) adjunctive therapy in children with DS or LGS (NCT03650452). Methods was a phase 2, randomized, double‐blind, placebo‐controlled study (≤300 mg twice daily, weight‐adjusted) (aged 2–17 years) DS, demonstrating three more convulsive seizures/month, LGS, four drop...
Background and purpose: High levels of glutamic acid decarboxylase (GAD)‐ab were initially described in patients with stiff person syndrome, have since also been observed other neurological diseases. Temporal lobe epilepsy (TLE) seems to be specially associated. Our purpose is describe the prevalence GAD‐ab TLE, characterize clinical‐immunological profile TLE high GAD‐ab. Methods: An immunological including antinuclear, anti‐DNA, anti‐cardiolipin, anti‐transglutaminase antithyroid antibodies...
Evaluate long-term effectiveness and tolerability of brivaracetam in clinical practice patients with focal epilepsy.This was a multicenter retrospective study. Patients aged ≥16 years were started on from November 2016 to June 2017 followed over 1 year. Data obtained medical records at 3, 6 12 months after treatment initiation for evaluation safety- seizure-related outcomes.A total 575 included analyses; most had been treated ≥4 lifetime antiepileptic drugs. Target dosage achieved by 30.6%...
Summary Objective To pool observational data on the routine use of perampanel to obtain information real‐world outcomes and in populations typically underrepresented clinical trials. Methods Individual‐level people with epilepsy treated at 45 European centers were merged into a single dataset. Prespecified were: 1‐year retention rate, seizure freedom rate (duration ≥6 months), incidence treatment‐emergent adverse events ( TEAE s). In addition, relationships explored logistic regression...
The noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist perampanel was shown in phase III trials to be an effective and well-tolerated adjunctive treatment for partial-onset seizures. In adolescents, it is necessary characterize cognitive, neuropsychological, behavioral side effects of antiepileptic drugs (AEDs). current analysis focuses on outcomes, efficacy, safety adolescents.Adolescents (12-17 years) a stable regimen 1-3 AEDs seizures were...
Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder associated with mutations in TSC1 and TSC2 genes, upregulation of mammalian target rapamycin signaling, subsequent tumor formation various organs. Due to the many manifestations TSC their potential complications, management requires expertise multiple medical disciplines. A multidisciplinary care approach recommended by consensus guidelines. Use teams (MDTs) has been shown be beneficial treating other diseases,...
The PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study was a analysis data from 44 real-world studies 17 countries, in which people with epilepsy (PWE; focal generalized) were treated perampanel (PER). Retention effectiveness assessed after 3, 6, 12 months, at the last visit (last observation carried forward). Effectiveness assessments included 50% responder rate (≥ reduction seizure frequency baseline) freedom (no seizures since least prior visit); PWE status...
Abstract Objective To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities etiologies. Methods EXPERIENCE/EPD332 was a pooled analysis individual patient records from several non-interventional studies patients initiating BRV clinical practice. Outcomes included ≥ 50% reduction baseline seizure frequency, freedom (no seizures within prior 3 months), continuous since baseline), discontinuation, treatment-emergent adverse events...
Abstract Objective To estimate time to onset of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]), we conducted post hoc analyses data from two randomized, placebo‐controlled, Phase 3 trials, GWPCARE3 (NCT02224560) GWPCARE4 (NCT02224690), patients with Lennox–Gastaut syndrome. Methods Patients received plant‐derived pharmaceutical formulation highly purified CBD (Epidiolex, 100 mg/ml oral solution) at 10 mg/kg/day (CBD10; GWPCARE3) or 20 (CBD20; both trials)...
IntroductionEpilepsy is a serious neurological disease, ranking high in the top causes of disability. The main goal its treatment to achieve seizure freedom without intolerable adverse effects. However, approximately 40% patients suffer from Drug-Resistant Epilepsy (DRE) despite availability latest options called third-generation Anti-Seizure Medications(ASMs). Cenobamate first ASM approved Spain for adjunctive Focal-Onset Seizures (FOS) adult with DRE. introduction new drug increases number...